The key aspects of this award are:
Impact: The SRA is intended to support research designed to have a major impact on the health and well-being of melanoma survivors, their families, and/or caregivers. Impactful research will accelerate the movement of promising ideas into clinical applications or other real-world applications and advance the field of melanoma-specific quality of life and survivorship.
Study Design: Applications should clearly articulate and justify the chosen study design. Studies proposing retrospective analyses or prospective enrollment should clearly describe the architecture of the study (e.g., descriptive, correlational, field experimental, meta-analyses) and the study population(s). The study population(s) should be representative of the people who are anticipated to benefit from the research. If applicable, questionnaires should be described in sufficient detail to justify interpretation of potential results.
Melanoma Consumer Collaboration: For the purposes of the SRA, a melanoma consumer is defined as a melanoma survivor, family member, and/or caregiverwho can provide lived experience expertiseto the research project team . Applicants to the SRA are required to establish a collaborative research approach with the melanoma consumer community to maximize the impact and translatability of the research for the benefit of the intended melanoma community(ies). The research team must include at least one melanoma consumer or a melanoma-community supporting organization who will be integral to the planning, execution, and implementation of the proposed research. The role of the melanoma consumer collaborator(s) should include providing objective input on the research question being addressed; the study design, execution, and evaluation; and the potential impact of the research outcomes on the health and well-being of melanoma survivors, their families, and/or their caregivers. The melanoma consumer collaborator(s) should be active participants and integrated into the research team; their participation should not be limited only to passive activities (e.g., attending seminars or quarterly team meetings). Additional information and resources for establishing a collaborative research approach with the melanoma consumer community is provided below.
Other Important Considerations:
Collaborative Research Approaches: Collaborative research approaches create partnerships between scientific researchers and, for the purposes of the SRA, melanoma consumers to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and melanoma consumers collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure non-tokenistic involvement of the melanoma consumers within the research team. Research results are jointly interpreted, disseminated, and fed back to affected communities and in some instances may be translated into interventions or policy.
Collaborative relationships with the melanoma consumer community may be established through integrating melanoma consumers and/or melanoma-community supporting organizations into research teams as co-researchers, advisors, and/or consultants. Examples for implementing collaborative research approaches are listed below, but each research team may pursue other options as appropriate for the proposed research:
The research team includes at least one melanoma consumer who will provide advice and consultation throughout the planning and implementation of the research project. The consumer(s) should be able to speak to the needs of the melanoma consumer community, not just speak to their own personal experiences.
The research team establishes partnerships with at least one community-supporting organization that provides advice and consultation throughout the planning and implementation of the research project. Community-supporting organizations may include advocacy groups or other formal organizational stakeholders that can speak to the needs of the melanoma consumer community.
The research team assembles a melanoma consumer community advisory board. The advisory board may include melanoma consumers, a coalition of community-supporting organizations, or any combination thereof that provides advice and consultation throughout the planning and implementation of the overall program and/or individual research projects.
Background
The Survivorship Research Award (SRA) is being offered for the first time in FY24. The vision of the Melanoma Research Program (MRP) is to prevent melanoma initiation and progression, and reduce hardship. The mission is to support development of earlier interventions to enhance mission readiness, diminish melanoma burden, and improve quality of life for Service Members, Veterans, their Families, and the American public.
Grant Details
The SRA aims to address the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families, and/or their caregivers. The award supports development of evidence-based practices, behavioral health science, survivor and/or caregiver well-being interventions and surveillance, and/or identification of psychosocial survivor outcomes.
Clinical trials are allowed. The award also emphasizes collaborative research approaches with the melanoma consumer community to maximize impact and translatability of the research.
Eligibility Requirements
Extramural and Intramural organizations are eligible to apply, including foreign or domestic organizations, for-profit and non-profit organizations, and public entities. The named Principal Investigator (PI) on the application must be an independent investigator at any career level.
Cost sharing/matching is not an eligibility requirement.
Period of Performance
Awards supported with FY24 funds will be made no later than September 30, 2025. The period of performance for an FY24 MRP Survivorship Research Award should not exceed $725,000.
Grant Value
The CDMRP expects to allot approximately $2.3M to fund approximately two Survivorship Research Award applications.
The total value of the grant is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review.
Place of Performance
The SRA seeks to support research that is relevant to the healthcare needs of Service Members, Veterans, and/or their Families.
Applications from investigators within the military Services and applications involving multidisciplinary collaborations among academia, industry, the military Services, U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged.